Gliclazide Dosing for 87kg Male
For an 87kg adult male with normal renal function, start gliclazide immediate-release at 40-80 mg once daily taken 30 minutes before breakfast, or start gliclazide modified-release at 30 mg once daily with breakfast, titrating upward based on glycemic response.
Starting Dose by Formulation
Immediate-Release (IR) Formulation
- Initial dose: 40-80 mg once daily 1
- Must be taken 30 minutes before breakfast for optimal absorption and postprandial glucose control 2
- Taking gliclazide immediately before or after meals results in poor absorption, delayed insulin response peaks (2-3 times longer), and prolonged postprandial hyperglycemia 2
- Maximum dose: 320 mg daily (divided into 2 doses if >160 mg) 3, 4
Modified-Release (MR) Formulation
- Initial dose: 30 mg once daily 3
- Can be taken with food without affecting absorption (unlike IR formulation) 3
- The hydrophilic matrix provides progressive 24-hour drug release matching the glycemic profile 3
- Maximum dose: Up to 270 mg daily may be used for optimal efficacy without exceeding hypoglycemia risk of IR formulation 4
- Standard maximum listed as 120 mg, though modeling suggests 270 mg may be appropriate 3, 4
Titration Strategy
- IR formulation: Increase by 40-80 mg increments every 1-2 weeks based on fasting and postprandial glucose 1
- MR formulation: Increase by 30 mg increments at monthly intervals based on HbA1c and glucose monitoring 3
- Target: HbA1c <7% while minimizing hypoglycemia risk 4
Weight Considerations
- Body weight does not require dose adjustment for gliclazide, as it is dosed based on glycemic response rather than weight 1
- The 87kg weight is within normal adult range and does not necessitate starting at higher or lower doses 3, 1
Renal Function Context
- With normal renal function, standard dosing applies without adjustment 5
- Gliclazide is primarily hepatically metabolized with only 4% renal clearance, making it safer than renally-cleared sulfonylureas 1
- If renal function were impaired (eGFR <30), starting dose would be reduced to 30 mg daily with cautious titration 5
Efficacy Expectations
- Maximum effect achieves HbA1c <7% in approximately 44% of patients 4
- Most efficacious in patients previously treated by diet alone, with HbA1c reductions of 0.9-0.95% sustained over 24 months 3
- Gliclazide specifically improves abnormal first-phase insulin release characteristic of type 2 diabetes 1
Safety Profile
- Hypoglycemia risk: Lower incidence compared to other sulfonylureas due to insulin secretion pattern 1
- Nocturnal hypoglycemia is rare; symptomatic hypoglycemia occurs in approximately 5% of patients 3
- Modeling shows 11% of patients experience glucose <3 mmol/L, with the most sensitive 5% experiencing 35 minutes of hypoglycemia 4
- Weight neutral: Body weight remains stable during treatment 3
Critical Timing Consideration
For immediate-release formulation, the 30-minute pre-meal timing is non-negotiable 2. Taking it at the wrong time relative to meals dramatically impairs both drug absorption and glycemic control, essentially wasting the dose and leaving the patient with prolonged hyperglycemia 2.